Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017132059 - INACTIVATION OF VIRUSES BY DELIPIDATION

Publication Number WO/2017/132059
Publication Date 03.08.2017
International Application No. PCT/US2017/014267
International Filing Date 20.01.2017
IPC
C07K 14/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
C12N 7/06 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
06by chemical treatment
CPC
A61K 2039/521
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
52Bacterial cells; Fungal cells; Protozoal cells
521inactivated (killed)
A61K 2039/5252
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
525Virus
5252inactivated (killed)
A61K 2039/552
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
55characterised by the host/recipient, e.g. newborn with maternal antibodies
552Veterinary vaccine
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Applicants
  • ELANCO US INC. [US]/[US]
Inventors
  • DIAZ, Leyla
  • WU, Stephen
Agents
  • PFLUGH, David, L.
  • MCGRAW, Elizabeth A.
Priority Data
62/287,48827.01.2016US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) INACTIVATION OF VIRUSES BY DELIPIDATION
(FR) INACTIVATION DE VIRUS PAR DÉLIPIDATION
Abstract
(EN) The present invention relates to vaccines containing enveloped viruses whose envelopes have been depleted of lipids using methyl β-cyclodextrin (MBCD). Delipidation of enveloped viruses in a two-step process abolishes the infectivity of those viruses, which allows delipidated viruses to be used safely in vaccines. Use of MBCD to deplete lipids such as cholesterol, in contrast to other methods, results in viruses with less than 20% of the cholesterol of an untreated virus but such delipidated viruses retain at least 85% of the protein content of an untreated virus. Delipidation by MBCD also preserves the immunogenicity of the viral proteins. The present invention of using MBCD treatment in a two-step process to delipidate enveloped virus represents a new alternative for generation of inactivated viruses which are incorporated into effective vaccines.
(FR) La présente invention concerne des vaccins comprenant des virus enveloppés dont les lipides des enveloppes ont été épuisés à l'aide de méthyl-β-cyclodextrine (MBCD). La délipidation des virus enveloppés dans un procédé en deux étapes supprime l'infectivité de ces virus, ce qui permet aux virus délipidés d'être utilisés en toute sécurité dans des vaccins. L'utilisation de MBCD en vue d'épuiser des lipides tels que le cholestérol, contrairement à d'autres procédés, a pour conséquence des virus présentant moins de 20 % du cholestérol d'un virus non traité mais ces virus délipidés conservent au moins 85 % de la teneur en protéines d'un virus non traité. La délipidation par MBCD préserve également l'immunogénicité des protéines virales. La présente invention, consistant à utiliser un traitement par MBCD dans un procédé en deux étapes pour la délipidation du virus enveloppé, constitue une nouvelle alternative pour la génération de virus inactivés qui sont incorporés dans des vaccins efficaces.
Related patent documents
CL2018-1978This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
TH1801004414This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau